fashion -WSS

fashion

author：fashion 2025-10-02 18:49:22 - browse：5

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Is there really a nursing shortage in the U.S.?

focus

WSS

Biden jokes that Republicans may impeach him because inflation is starting to cool down

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

STAT Summit: Ending the crisis of Black deaths in the U.S.

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Is there really a nursing shortage in the U.S.?

Interest rates are at a 22

knowledge

fashion

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

CDC: Cases of alpha

DIEP, the 'gold standard' of breast reconstruction, is under threat

Study on Amgen’s bispecific immunotherapy produces positive data

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CZI to create biohub to build anti

Medical records are filled with copy

STAT Summit: The economic case for universal basic health care

Walensky prepares to leave CDC — and Congress — behind

STAT Readout: Friday, Oct. 20 biotech updates

explore

Roche acquires Telavant from Roivant, adding experimental IBD treatment

VC firm RA Capital starts a new synthetic biology incubator

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Questions loom on AstraZeneca cancer drug as safety concerns ebb